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Abstract 
Background:  Vaccination with inactivated (killed) whole‑virus particles has been used to prevent a wide range of 
viral diseases. However, for an HIV vaccine this approach has been largely negated due to inherent safety concerns, 
despite the ability of killed whole‑virus vaccines to generate a strong, predominantly antibody‑mediated immune 
response in vivo. HIV‑1 Clade B NL4‑3 was genetically modified by deleting the nef and vpu genes and substitut‑
ing the coding sequence for the Env signal peptide with that of honeybee melittin signal peptide to produce a 
less virulent and more replication efficient virus. This genetically modified virus (gmHIV‑1NL4‑3) was inactivated and 
formulated as a killed whole‑HIV vaccine, and then used for a Phase I human clinical trial (Trial Registration: Clinical Tri‑
als NCT01546818). The gmHIV‑1NL4‑3 was propagated in the A3.01 human T cell line followed by virus purification and 
inactivation with aldrithiol‑2 and γ‑irradiation. Thirty‑three HIV‑1 positive volunteers receiving cART were recruited for 
this observer‑blinded, placebo‑controlled Phase I human clinical trial to assess the safety and immunogenicity.
Results:  Genetically modified and killed whole‑HIV‑1 vaccine, SAV001, was well tolerated with no serious adverse 
events. HIV‑1NL4‑3‑specific PCR showed neither evidence of vaccine virus replication in the vaccine virus‑infected 
human T lymphocytes in vitro nor in the participating volunteers receiving SAV001 vaccine. Furthermore, SAV001 with 
adjuvant significantly increased the pre‑existing antibody response to HIV‑1 proteins. Antibodies in the plasma of 
vaccinees were also found to recognize HIV‑1 envelope protein on the surface of infected cells as well as showing an 
enhancement of broadly neutralizing antibodies inhibiting tier I and II of HIV‑1 B, D, and A subtypes.
Conclusion: The killed whole‑HIV vaccine, SAV001, is safe and triggers anti‑HIV immune responses. It remains to be 
determined through an appropriate trial whether this immune response prevents HIV infection.
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Background
Despite the tremendous advances in immunology and 
molecular biology accomplished since the discovery 
of HIV-1 [1], results of vaccine trials against HIV have 
remained extremely poor. Only one trial out of more than 
one hundred showed a modest protection while all the 
others did not induce any protective immunity against 
the virus [2–7]. Overall there is, therefore still a need to 
propose unexplored avenues. Here, we decided to explore 
the use of a full inactivated virus as immunogen, the most 
classical vaccine track [8–13] that has, however, never 
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been adequately studied thus far, since the only attempt 
has been that of Jonas Salk with his Remune [14] which 
has been shown to have lost its envelope glycoprotein.
Vaccination with whole, inactivated (killed) virus par-
ticles has been used to prevent a wide range of viral dis-
eases [8–13]. However, for inherent safety concerns, this 
approach has been largely negated for HIV-1 vaccine 
despite the ability of inactivated but intact whole-virus 
vaccines to generate a strong, predominantly antibody-
mediated immune response in  vivo. Previous develop-
ments in inactivation methods have greatly enhanced the 
utility of these immunogens [11, 15–18]. These chemicals 
allow elimination of virus infectivity to undetectable lev-
els while maintaining the native protein conformation, 
including that of the important HIV-1 viral envelope 
surface glycoprotein (gp120) which is the major target 
for neutralizing antibody response in  vivo [19, 20]. The 
killed whole-HIV-1 vaccine approach has great merit as it 
has the potential to present multiple viral antigens to the 
immune system in their native conformations. Thus, sev-
eral scientists have recently suggested that it is time for 
another look at inactivated (killed) HIV vaccine for pre-
vention of HIV infection [21, 22]. Interestingly, only one 
group (Remune) previously attempted a killed whole-
HIV vaccine. However, lack of gp120 on the virion sur-
face and other safety concerns led to the discontinuation 
of their project [14].
The challenges in developing a killed whole-HIV vac-
cine include safety issues associated with virus produc-
tion and completely “killing” the virus on a large scale. 
In the present study, we demonstrate the result of our 
recently conducted Phase I human clinical trial for safety 
evaluation of our killed whole-HIV-1 vaccine, SAV001. 
The primary objective of this study was to evaluate the 
safety and tolerability of a single dose of SAV001 (with or 
without adjuvant, Montanide®ISA51VG) administered 
intramuscularly in men and women with chronic HIV-1 
infection who were on cART. As a secondary measure, 
we also evaluated the vaccine-elicited humoral immune 
responses against the structural proteins of HIV-1 




The nef -, vpu-, and the Env-signal peptide replaced the 
virus used in this study were generated from the HIV-1 
Clade B infectious molecular clone, pNL4-3 (The NIH 
AIDS Reagent Program). The fragment between BsmBI 
and BglII (159 base pairs from 104 to 263 nucleotides) in 
the upstream of nef gene (modified from Flint et al. [23]) 
was deleted and the stop codon (TAG) was inserted in 
order to generate attenuated HIV-1. The coding region of 
HIV-1 env signal peptide (30 amino acids) was replaced 
by the coding sequence of honeybee melittin signal pep-
tide (21 amino acids) [24] in order to increase the effi-
ciency of this genetically modified HIV-1 replication. 
The vpu gene was deleted as the result of the Env signal 
peptide gene replacement due to its overlapping reading 
frame in the upstream of env gene (Fig. 1). The pNL4-3 
M/dNef with env signal peptide replaced plasmid was 
transfected into A3.01 human T-lymphocytes and recov-
ered the genetically modified HIV-1 NL4-3 (gmHIV-
1NL4-3) virus. To confirm the genetic modification we 
RT-PCR amplified the SAV001-specific viral RNA using 
a primer specific for the honeybee melittin signal peptide 
coding sequence.
Characterization of gmHIVNL4‑3 virus
The electron microscopy was carried out by placing 
gmHIV-1NL4-3 virus in SAV001 vaccine onto a carbon 
grid, negatively stained with 1% PTA, and then exam-
ined in a Philip EM300 transmission electron micro-
scope. Western blot analyses using HIV-1 p24 antiserum 
(The NIH AIDS Reagent Program) and goat anti-HIV-1 
gp120 polyclonal antibody (BIODESIGN), respectively, 
carried out by the standard procedure to show the pres-
ence of capsid protein p24 and gp120 glycoprotein on 
SAV001 vaccine. Aggregation of CD4+ human T cell 
lines was examined by fluorescent microscopy after 
addition of SAV001 vaccine virus to CD4+ human T 
cell lines, AA2 and A3.01. Cultured AA2 and A3.01 cells 
were incubated with SAV001 vaccine virus for 30  min 
and examined under fluorescent microscope. To demon-
strate that intact gp120 is present on the gmHIV-1NL4-3 
(SAV001) vaccine virus, five 8  week-old Wistar rats per 
group were prime-immunized with 20  µg of SAV001 
vaccine which was mixed 1:1 with Montanide. The rats 
were boost-immunized with the same concentration of 
the SAV001 three weeks after the prime-immunization. 
Blood from the immunized rats was collected one week 
after the boost-immunization and gp140 trimer was used 
as an antigen (The NIH AIDS Reagent Program) to detect 
gp120-specific antibodies in the immunized rat sera by 
ELISA.
GMP manufacturing of SAV001
The killed whole-gmHIV-1NL4-3 was manufactured in the 
cGMP facility of Omnia Biologics, Inc. (Rockville, MD, 
USA) with total 120 l scale. The infectious gmHIV-1NL4-3 
virus titer was measured by TCID50 assay using AA-2 
human T lymphocyte. The infected culture fluid was 
inactivated, concentrated and purified by sucrose gradi-
ent ultracentrifugation. SAV001 was released for Phase I 
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clinical trial based on the results of purity, identity, steril-
ity, and safety tests under the GLP conditions.
Inactivation processes of gmHIV‑1NL4‑3 virus
Double inactivation procedures were used for completely 
killing gmHIV-1NL4-3 virus during GMP manufacturing 
processes, respectively. The purified viruses from harvest 
underwent a chemical inactivation step by incubating 
the virus with a 2.5 mM solution of 2-2′-dithiodipyridine 
(aldrithiol-2 or AT-2) for 2 h at 37 °C with shaking.
Gamma Irradiation was performed off-site at STERIS 
Isomedix services at the end of manufacturing pro-
cess. Grid boxes containing filled vials were irradi-
ated via a Cobalt-60 source, receiving a dose of 30 KGy 
(3,000,000 rads) of gamma radiation (Table 1).
Study vaccine, adjuvant, and placebo
Genetically modified gmHIV-1NL4-3 virus (Fig.  1) was 
propagated in A3.01 human T-cell line, purified through 
the down-stream purification procedures and inactivated 
with a 2.5 mM solution of aldrithiol-2 (AT-2) for 2 h at 
37 °C followed with γ-irradiation with a Cobalt-60 source, 
exposing a dose of 30 kGy (3,000,000 rads) of γ-radiation. 
Samples were tested through >230 product release assays 
at the GLP facilities to measure any residual virus rep-
lication or impurities according to the US FDA man-
dated product release tests. SAV001 was supplied in 
a 400  µl aliquot containing 160  µg (100  µg/0.25  ml) of 
total gmHIV-1NL4-3 virus protein which was then for-
mulated with 75  mM NaCl, 25  mM HEPES pH7.4 
with 5% trehalose mixed with an equal volume of 
Fig. 1 Construction of nef‑, vpu‑, and glycoprotein signal peptide replaced HIV‑1NL4‑3 (gmHIV‑1NL3‑4) and characterization of the SAV001 vaccine 
virus: The fragment between BsmBI and BglII (from 104 to 263 nucleotides) of HIV‑1 NL4‑3 nef gene was deleted and the stop codon (TAG) was 
inserted (a). The coding region of HIV‑1 env signal peptide (30 amino acids) was replaced by the coding sequence of honeybee melittin signal 
peptide (21 amino acids) [24] (c). The vpu gene was deleted as the result of the Env signal peptide gene replacement due to its overlapping reading 
frame in the upstream of env gene. The pNL4‑3 M/dNef with env signal peptide replaced plasmid was transfected into A3.01 human T‑lymphocytes 
and recovered the genetically modified HIV‑1 NL4‑3 (gmHIV‑1NL4‑3) virus (b). The genetic modification was confirmed by RT‑PCR using honeybee 
melittin‑specific primer with modified nef gene‑specific primer (d). Electron micrograph of SAV001 vaccine showing intact virion (e). Western 
blot analyses of SAV001 using HIV‑1 p24 antiserum (The NIH AIDS Reagent Program) and goat anti‑HIV‑1 gp120 polyclonal antibody (BIODESIGN), 
respectively (f). Aggregation of CD4+ AA2 [g, h (arrow)], and A3.01 [i, j (arrow)], as a result of gp120 on the SAV001 vaccine virus binding to the cell 
surface receptors. Induction of anti‑gp120 antibody in SAV001 vaccine immunized rat sera using the gp140 trimer by ELISA (k, l)
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adjuvant, Montanide®ISA51VG (Seppic, France). 
Montanide®ISA51VG is an oil-in-water emulsion. The 
surfactant mannide monooleate in Montanide®ISA51VG 
contains vegetable-grade oleic derived from olive oil [25]. 
Preservative-free sterile isotonic saline (0.9%) was used as 
the placebo. The Phase I human clinical trial of SAV001 
was cleared by the US FDA for human clinical trials (Trial 
Registration: Clinical Trials NCT01546818).
Study design and population
This study was randomized, observer-blinded, and pla-
cebo-controlled with or without adjuvant administered 
intramuscularly as a single dose. A total of thirty-three 
(n =  33) subjects enrolled into the study and were ran-
domly assigned to groups (Fig. 2). The subjects were pre-
screened and eligibility evaluated for the study. After a 
28 day screening period, subjects were randomized into 
2 groups. The Full Analysis Set (FAS) and the Safety Set 
included 33 subjects (13 in the SAV001 group, 4 in the 
Placebo group, 12 in the SAV001 + Adjuvant group, and 
4 in the Placebo + Adjuvant group; Table 2). The major 
reasons for screen failure were renal dysfunction, higher 
plasma HIV-1 RNA level, or lower CD4+ T cell counts.
The study population consisted of adult males (n = 29) 
and females (n = 4) with chronic HIV infection who were 
undergoing treatment with cART, viral load with HIV-1 
RNA levels of <75 copies/ml, and CD4+ T-cell count of 
at least 350 cells/μl for at least 6 months. Female subjects 
underwent a serum or urine pregnancy test before vacci-
nation. Sexually active subjects agreed to use an effective 
method of contraception from the day of vaccination for 
four months.
In group 2, SAV001 or saline was mixed with the adju-
vant prior to injection at the site in a 1:1 vol/vol ratio 
(0.25  ml each) for a final injection volume of 0.5  ml/
dose. Because of solution appearance differences, 
100  µg of SAV001 was administered by an unblinded 
member and ensured that investigator and subject 
remained blinded.
The study was conducted with prior written approval 
of a properly constituted institutional review board. 
Informed consent was obtained from each subject 
according to regulatory and legal requirements.
Determination of residual infectious virus in SAV001 
vaccine
 One hundred million CD4+ A3.01 human T cells were 
infected with either 5  ×  107 TCID50 of the wild type 
HIV-1NL4-3 virus or 5  ×  107 TCID50 of gmHIV-1NL4-3 
virus, or 30 human doses (3  mg) of SAV001 vaccine 
with assumption that all cells will be infected at second 
or third passages of infected cells. Samples were incu-
bated for 1 h for virus adsorption, culture media added, 
and incubated in a 37  °C CO2 incubator. Infected cells 
were split every 3 days and refurbished with fresh A3.01 
cells. The infected cells were harvested at the time of 
each subculturing and stored at −20  °C. Infected cellu-
lar DNA was extracted and assessed by PCR using a pair 
of primers covering the 5300–6473 nucleotide region of 
HIV-1 NL4-3 genome (Fig.  3a Product 1). This region 
produces a 1173  bp PCR product and another pair of 
primers spanning 459–2523 nucleotides of HIV-1 NL4-3 
genome (Fig. 3a Product 2) which will produce a 2064 bp 
PCR product.
Table 1 Inactivation steps in virus production and the log reduction at each inactivation step
Harvest viruses from 




Diafiltration   Chemical 
Inactivation  
2.5mM solution of 





Resuspended in  
Formulation Buffer 




Inactivation method Log10 reduction Master virus bank (Log10TCID50/ml) Putative safety margin
AT‑2 ≥4.83 ± 0.26 5.64 ± 0.10 ≥4.71 log units
Gamma irradiation ≥5.52 ± 0.33
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Sequence analysis of virus from HIV patients by 454 
pyrosequencing
To detect any SAV001 vaccine virus specific DNA the 
proviral DNA in 106 PBMCs from each participant was 
extracted with QIAamp DNA blood kit (Qiagen), with 
which nested PCR was used to amplify ~2.8 kb of HIV-1 
env fragments. Pyrosequencing of the HIV-1 in plasma 
was performed following reverse transcription-PCR to 
obtain the gp120 env DNA amplicons. Nested PCRs of 
the C2–V3 regions were prepared for pyrosequencing 
using the external gp120 env products as templates. The 
primers E110 and E125 [26] were modified to contain 
the 454 adaptor sequences (Roche Lib-A Primer A and 
Primer B), followed by a 10 basepair Multiplex Identifier 
(MID) sequence at the 5′ end to permit sample pooling. 
These barcoded amplicons were quantified by fluorom-
etry with the Quant-iT PicoGreen dsDNA Assay Kit (Life 
Technologies), pooled in equimolar concentrations, and 
sequenced on a 454 GS Junior System (Roche Diagnos-
tics) using the GS Junior Titanium Sequencing chemistry. 
The resulting reads were trimmed to exclude the MIDs 
and primer sequence, and low-quality reads were filtered 
using the GS Run Processor according to length and 
quality scores.
The proviral DNA in 106 PBMCs from each of the 
participant HIV patients was extracted with QIAamp 
DNA blood kit (Qiagen), with which nested PCR was 
used to amplify ~2.8  kb of HIV-1 env fragments. The 
external primers were envA (forward, HXB2 number-
ing nt5954–5982, 5′-GGCTTAGGCATCTCCTATG-
GCAGGAAGAA-3′)/envN (backward, nt9145-9171, 
5′-CTGCCAATCAGGGAAGTAGCCTTGTGT-3′), and 
the internal primers were envB (forward, nt6202–6228, 
5′-AGAAAGAGCAGAAGACAGTGGCAATGA-3′)/
envM (backward, nt9068–9096, 5′-TAGCCCTTC-
CAGTCCCCCCTTTTCTTTTA-3′). The PCR amplifi-
cations were performed with 5  μl of extracted proviral 
DNA and the following conditions: 98 °C 2 min, [98 °C 
10  s, 63  °C 30  s, 72  °C 2  min] ×  35 cycles, and 72  °C 
10  min. The PCR products were purified with a 
QIAquick gel extraction kit (Qiagen). To perform the 
454 pyrosequencing, we used the following prim-
ers: E110 (forward, nt7002–7025, 5′-CTGTTAAATG-
GCAGTCTAGCAGAA-3′) and E125 (backward, 
nt7315–7338, 5′-CAATTTCTGGGTCCCCTCCT-
GAGG-3′) with 66 different barcodes at the 5′ ends of 
the both primers. Amplicons were purified using the 
Agencourt AMPure XP (Beckman Coulter) magnetic 
Fig. 2 Flow diagram. The study was a randomized, observer‑blinded, placebo‑controlled study of killed‑whole HIV‑1 vaccine (SAV001‑H) with or 
without adjuvant administered intramuscularly. Patients were screened for participation in this study within 28 days before enrollment. A total of 33 
patients were planned to be enrolled in this study and randomized into Groups 1 and 2 of 17 and 16 patients, respectively. Patients were randomly 
assigned in a 9:3 ratio to receive either a single injection of the active investigational product or placebo, each of which was administered either 
without (Group 1) or with (Group 2) adjuvant
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bead PCR purification system, quantified using the 
Quant-iT PicoGreen dsDNA Assay Kit (Life Tech-
nologies), and then equalized to a concentration of 
10  ng/μl. Samples were pooled into two tubes to pre-
vent redundancy of barcoded primer used for the 
amplification of samples. Amplicons were added to 
the emulsion at one copy per bead. EmPCR was done 
according to the Roche EmPCR manual, and Ampli-
con sequencing was performed according to the Roche 
Amplicon sequencing manual. Sequences were pro-
cessed and collected using Roche GS FLX System 
software. Following sequencing collection, sequences 
were extracted according to barcode by the Java script 
Extraction and sorted by barcode into a folder con-
taining two different files. The resulting reads were 
trimmed to exclude the MIDs and primer sequence, 
and low-quality reads were filtered using the GS Run 
Processor according to length and quality scores. 
Table 2 Characteristics of the study subjects
ND not done
a Native American and black
b Mexican
c Approximate days
d Evaluated at screening day






Plasma HIV‑1 RNA 
level at entry (cop‑
ies/ml)
SAV001 2001004 43/male/black B 537 1826 <2.00E+1
1001005 37/male/white ND 443 570 <2.00E+1
2001008 40/male/white B 1380 830 <2.00E+1
2001009 28/male/white A 960 500 <2.00E+1d
2001012 27/male/white B 1832 598 <2.00E+1
3001015 35/male/white B 1185c 694 2.50E+1
3001018 44/male/white B 1430 804 <2.00E+1
2001022 30/male/white B 229 419 <2.00E+1
3001024 50/male/white B 1097 486 2.22E+1
1001025 44/female/white B 2478 574 <2.00E+1
4001029 30/male/black B 445 491 <2.00E+1
3001032 46/female/othera ND 1885c 440 <2.00E+1
3001033 45/male/white B 395c 515 <2.00E+1
Placebo 2001002 25/male/white B 1011 702 <2.00E+1
2001013 46/male/white ND 573 618 <2.00E+1
1001020 48/male/white B 1843 754 <2.00E+1
3001027 25/male/white B 265 366 <2.00E+1
SAV001 + adjuvant 1001001 46/male/white B 1269 539 <2.00E+1
1001003 49/male/white A 1289 833 <2.00E+1
2001006 21/male/white B 333 581 <2.00E+1
2001010 46/male/white B 4745c 739 <2.00E+1
2001011 33/female/black B 1559 369 <2.00E+1
3001016 48/male/white B 730c 626 <2.00E+1
3001017 43/male/white B 1550 459 <2.00E+1
3001019 35/male/Asian A 2220c 555 <2.00E+1
2001021 49/male/white B 1848 1079 <2.00E+1
3001026 29/male/white C 252 485 <2.00E+1
4001028 41/male/black A 637 449 <2.00E+1
4001031 40/male/white ND 1290 794 <2.00E+1
Placebo +adjuv. 1001014 47/male/white B 970c 827 <2.00E+1
2001007 48/male/asian D 638 498 <2.00E+1
1001023 49/male/white B 1316 1057 <2.00E+1
4001030 25/female/otherb B 448 519 <2.00E+1
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The sequence reads were used to generate phyloge-
netic trees for further analysis through alignment with 
the reference viral sequences including NL4-3, 1 or 2 
strains from HIV-1 subtype A (A1.AU.03.PS1044_Day0.
DQ676872; A2.CM. 01.01CM_1445MV.GU201516), B 
(B.US.98.1058_11.AY331295), C (C.ZA.04.04ZASK146.
AY772699), D (D.CM.01.01CM_4412HAL.AY371157), 
and F (F1.FR.96.96FR_MP411.AJ249238; F2.CM.02.02 
CM_0016BBY.AY371158), as well as CRF07-BC (0.07_
BC.CN.05.XJDC6431_2.EF368372) and CRF08-BC (08_
BC.CN.97.97CNGX_6F.AY008715).
Recognition of cell surface HIV‑1 trimeric gp120 by anti 
sera from vaccinated subjects
To evaluate recognition of trimeric HIV-1 envelope gly-
coproteins (Env) by the elicited antibodies, CEM.NKr 
cells infected with full-length pNL4.3 GFP ADA Env 
(WT) or deleted for nef- (N-) and vpu (U-) were stained 
at 48 h post-infection with 1/1000 dilution of HIV+ sera 
from SAV001 + Adjuvant, SAV001, Placebo + Adjuvant, 
or Placebo subjects and then labeled with an Alexa-
Fluor-647 conjugated anti-human IgG secondary anti-
body and analyzed by flow cytometry [27, 28].
Fig. 3 Absence of residual infectious HIV‑1 in SAV001 vaccine after inactivation: Detection of HIV‑1 proviral DNA in infected cells by PCR and 
sequence analysis of viruses isolated from HIV‑1 positive volunteer study subjects by 454 pyrosequencing. Lanes 1 Passage 3 of SAV001 vaccine virus 
infected cell DNA; Lanes 2 Passage 5 of SAV001 vaccine virus infected cell DNA: Lanes 3 Passage 10 of SAV001 vaccine virus infected cell DNA; Lanes 4 
Passage 3 of HIV‑1 NL4‑3 wild type virus infected cell DNA; Lanes 5 Passage 3 gmHIV‑1NL4‑3 mutant virus infected cell DNA (a). Multisequence align‑
ments of reads were constructed using MUSCLE (PMID: 15034147), and all phylogenetic analysis was performed with MEGA5 (PMID: 21546353). 
The sequence reads were used to generate phylogenetic trees for further analysis through alignment with the reference viral sequences including 
NL4‑3, 1 or 2 strains from HIV‑1 subtype A, B, C, D, and F (b, c). All numbers represent subject ID in S (SAV001 group); SA (SAV001 + Adjuvant group), 
P (Placebo group), and PA (Placebo + Adjuvant group). PA1001014 and S3001024 in b were randomly selected to show the detail data
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Assessment of safety
Adverse event (AE), local reaction, clinical laboratory, 
vital signs, physical examinations, and plasma HIV-1 RNA 
levels were assessed. Reporting began with the adminis-
tration of the study vaccine (Day 1) and continued until 
completion of study visit at Day 365. An AE was defined 
as any unfavorable and unintended sign, symptom, or 
disease temporally associated with the study vaccine, 
whether or not it was considered to be related to the vac-
cine. Subjected, observed, and elicited AEs were recorded 
using the terminology from the Medical Dictionary for 
Regulatory Activities. Investigators assessed the severity 
of each AE according to the DAIDS Table for Grading the 
Severity of Adult and Pediatric Adverse Events. If an AE 
occurred that was not graded by these criteria, its severity 
was evaluated as mild, moderate, severe, and potentially 
life threatening. The causality/relationship between the 
study vaccine and the AE was assessed as definite, prob-
able, possible, and unlikely depending on the symptom.
A serious AE (SAE) was defined as any untoward medi-
cal occurrence, if it resulted in death or was life threat-
ening, required inpatient hospitalization or persistent or 
significant disability. Pregnancy was not considered as 
a SAE, but all pregnancies that occurred within 90 days 
were reported by the investigator and subjects were dis-
continued from the study.
Each subject was instructed to complete a diary card 
for 7  days following study vaccine administration, to 
describe local reactions, systemic reactions, and other 
selected indicators of reactogenicity. If a reaction contin-
ued beyond 7 days after vaccination, it was recorded as 
an AE. Blood and urine samples were collected for hema-
tology, clinical chemistry and urinalysis, respectively.
Plasma HIV-1 RNA was quantitated by the Roche 
COBAS® Ampliprep/COBAS® TaqMan® HIV-1 test, 
V2.0 (Roche Molecular Diagnostics, California). If the 
subject was suspected to have an increase in plasma 
HIV-1 RNA, he/she was slated for an unscheduled visit 
within 2–4  weeks after the occurrence and retested 
plasma HIV-1 RNA.
Assessment of immunogenicity
The immunogenicity of the vaccine was assessed using 
the following humoral response and T-cell counts. The 
response was evaluated by assessment of antibody titers 
against p24, p17, gp120, and gp41 by standard ELISA.
Total CD3+ T cell count/μl, as well as CD4+ T-cell 
count/μl and CD8+ T-cell count/μl were quantified in 
peripheral blood by flow cytometry, and percentages 
of CD3+ CD4+ T-cells, and CD3+ CD8+ T-cells were 
calculated.
Assessment of neutralizing antibodies
Neutralization activity was measured using a luciferase-
based assay in TZM-bl cells as described at the protocol 
from Montefiori Laboratory, Duke University [29, 30]. 
The assays were performed with HIV-1 tier 2 PRB926-
04.A9.4237 (subtype B) [31], tier 1 HxB2. DG (subtype 
B) [32], 93UG065 (subtype D from Uganda)NIH ARP and 
Q168ENVa2 (subtype A) [33] ENV-pseudotyped viruses. 
Serum samples were heat-inactivated to destroy comple-
ment by incubation at 56 °C for 1 h before use. Because 
anticoagulants in plasma are toxic to the cells at low 
plasma dilutions, and in our experiment we found more 
than tenfold dilution did not influence the cell growth, so 
samples were first diluted by 1:10 followed by threefold 
serial dilutions in the 96-well plate, with Britelite (Per-
kin Elmer) using a Victor V plate reader (Perkin Elmer). 
The value of more than 50% reduction in relative lumi-
nescence units (RLU) compared to the control was deter-
mined as positive.
Statistical analysis
Due to the limited sample size of this study, it was likely 
that most inferential analyses would not be meaningful. 
Therefore, overall trends are reported. Continuous data 
were summarized by the group using descriptive statis-
tics and categorical data by the group using frequency 
tables (frequencies and percentages).
Results
The gmHIV‑1NL4‑3 used in SAV001 vaccine retained the 
intact virion structure and is immunogenic
The construction of the genetically modified gmHIV-
1NL4-3 virus is depicted in Fig.  1a–c and the sequences 
of the gmHIV-1NL4-3 genome have been confirmed by 
RT-PCR using honeybee melittin-specific primer with 
modified nef gene-specific primer (Fig. 1d). We examined 
the morphology of killed whole gmHIV-1NL4-3 virions in 
SAV001 by transmission electron microscopy. Virions 
in SAV001 remain intact after all purification and inac-
tivation processes (Fig.  1e). The presence of HIV-1 p24 
capsid protein and docking glycoprotein gp120 on the 
purified gmHIV-1NL4-3 virus particles was confirmed 
by Western blot (Fig.  1f ) and by aggregation of human 
T-cells in culture (Fig.  1g–j). In addition, SAV001 was 
found to be immunogenic in naïve rats. Intramuscular 
administration of SAV001 induced anti-gp120 antibody 
in rat as verified by ELISA titer (Fig. 1k, l). Results from 
these experiments provide clear evidence that purified 
and inactivated gmHIV-1NL4-3 virus used in SAV001 vac-
cine retained the intact virion structure including surface 
glycoprotein gp120.
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The gmHIV‑1NL4‑3 virus used in the SAV001 vaccine is 
completely inactivated
The complete inactivation of HIV-1 to generate a killed 
whole-HIV-1 vaccine is the most critical step to develop 
a killed whole-virus vaccine. We utilized two inactivation 
methods to effectively kill the gmHIV-1NL4-3 virus. The 
treatment of infected culture fluid with 2.5 mM of AT-2 
inactivates approximately 5 logs of gmHIV-1NL4-3 virus. 
The AT-2 treated viruses were then exposed to 30  KGy 
(3,000,000 rads) of γ-irradiation (Table 1). Based on con-
centration of virus particles and the inability to infect 
C8166 cells, we estimated a minimal 10.5 log reduction 
in viral infectivity per 0.25  ml of SAV001 vaccine. We 
conducted further experiments to determine whether 
or not SAV001 vaccine had any residual infectious 
gmHIV-1NL4-3 virus particles. We infected 107 A3.01 
human T-cells with 30 human doses (3 mg) of SAV001, 
passaged these killed virus-exposed (infected) cells 10 
consecutive times, isolated infected cell DNA, and tried 
to detect any HIV-1 proviral DNA genomic sequences 
by PCR using HIV-1NL4-3 virus specific primers. We did 
not find any HIV-1 NL4-3 proviral DNA sequences in 
SAV001 vaccine infected A3.01 cells (Fig. 3a). To further 
confirm the genetic mutation and safety of SAV001 vac-
cine, we attempted to reverse transcribe-PCR amplify 
the SAV001-specific viral RNA in the plasma of subjects 
using a primer specific for the honeybee melittin sig-
nal peptide coding sequence (Fig.  1d). As a control, we 
amplified a 960  bp product from viral RNA extracted 
from the gmHIV-1NL4-3 virus preparation but could not 
detect any of this viral RNA in the plasma of subjects. 
We then RT-PCR amplified the C2–V3 Env region of all 
participants before and for 4  weeks after vaccinations 
and analyzed the HIV-1 diversity/strain identity by 454 
pyrosequencing [26]. A total of 71,338 HIV-1 C2–C3 
(326 bp) env sequence reads were obtained from the 58 
plasma samples of 29 subjects (Fig.  3b). Most impor-
tantly, all sequence reads were participant-specific and 
we did not identify a gmHIV-1NL4-3 viral sequence in the 
>70,000 sequence reads by Next Generation Sequenc-
ing. These findings further confirm the lack of detect-
able gmHIV-1NL4-3 virus replication within SAV001 
vaccinated subjects (Fig.  3b). We concluded from these 
experiments that the gmHIV-1NL4-3 virus used in SAV001 
vaccine is completely inactivated.
The SAV001 vaccine is safe and well tolerated
There were no reports of potentially life-threatening 
AEs, SAEs, deaths, or AEs leading to study termina-
tion after vaccination in all groups. The most frequently 
reported System Organ Classes (SOCs) were GI disor-
ders, infections and infestations, and musculoskeletal 
and connective tissue disorders. The treatment groups 
were comparable with regards to intensity of AEs, and 
the majority of events reported were mild. Overall, sub-
jects from SAV001 + Adjuvant and Placebo + Adjuvant 
reported more AEs than subjects from SAV001 and Pla-
cebo. The adjuvant, Montanide®ISA51VG, is well-char-
acterized, water-in-oil emulsion adjuvant. There were 
no differences observed between groups with regards to 
relationship of AE to study drug (Table  3). The major-
ity of events were assessed as not/unlikely related to 
SAV001.
The majority of subjects reported no local or systemic 
reaction immediately after vaccination.
The most frequently reported local or systemic reac-
tions in daily diary cards for 7  days after administra-
tion were mild or moderate muscle pain, joint pain, 
tiredness, and other feelings of discomfort. In SAV001 
and Placebo, muscle pain reactions were not identified 
on Day 7 although 15.4% of subjects reported moder-
ate muscle pain on Day 1. Within SAV001  +  Adjuvant 
and Placebo  +  Adjuvant, the incidence of muscle pain 
was higher in subjects of SAV001 +  Adjuvant than Pla-
cebo +  adjuvant on Days 1 and 2; however, this pattern 
reversed on Days 3 through 7. Only one subject in the Pla-
cebo + Adjuvant experienced an increase in muscle pain 
severity from mild on day 1 to severe joint pain on Day 
7. No subjects reported swelling, rash, oral temperature 
≥38 °C, redness or skin hardening at the injection site.
Based on the above data, it is safe to conclude that 
SAV001 + Adjuvant did not cause any serious local, sys-
temic reactions, or adverse events. Therefore the study 
vaccine is tolerable for use in humans.
The SAV001 vaccine elicited humoral immune responses 
against the HIV vaccine components p24/p17/gp120 
and gp41
Despite that the main goal of the current study was to 
evaluate the safety of our inactivated vaccine in humans, 
we also evaluated some elicited humoral immune 
responses. High antibody titers against p24, p17, gp120, 
and gp41 were observed in all the subjects at baseline 
as expected, considering all the enrolled subjects were 
infected with HIV-1 and on cART. The SAV001 + Adju-
vant group had increased antibody titers against p24, 
p17, and gp120 proteins from baseline at all time points. 
In contrast, the SAV001 alone (without adjuvant) group 
showed insignificant increase of antibodies against HIV-1 
proteins (Fig. 4a–d).
Antibodies binding to monomeric HIV-1 gp120 are 
a poor surrogate for virus neutralization or clearance 
within vaccinated individuals [34]. Thus, we also meas-
ured binding of antibodies in plasma to CD4+ T cells 
expressing trimeric HIV-1 Env glycoproteins on the cell 
surface using flow cytometry [35]. Plasma from subjects 
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immunized with SAV001 with/without adjuvant had 
antibodies with enhanced recognition (p  =  0.0544 in 
SAV001, p  =  0.0524 in SAV001  +  Adjuvant) of the 
native trimeric Env protein as compared to the plasma 
from placebo subjects (p  =  0.5479 in SAV001  +  Adju-
vant) (Fig.  5). Interestingly, this trend became statisti-
cally significant (p  =  0.0109 in SAV001, p  =  0.018 in 
SAV001 + Adjuvant) when we measured recognition of 
Env protein at the surface of Nef- Vpu- HIV-1 infected 
cells where trimeric Env glycoprotein engages with sur-
face CD4 and exposes CD4-induced epitopes [27, 28, 36].
Augmented neutralizing antibodies in response to SAV001 
in a number of vaccine recipients
It is believed that a truly efficacious HIV vaccine should 
be able to harness the highly desired broadly neutraliz-
ing antibody response. Although the primary objective 
of this Phase I human clinical trial was an evaluation 
of the safety of a killed whole-HIV-1 vaccine, we tested 
the levels of neutralizing antibodies in plasmas of the 
vaccinated and control participants who are HIV posi-
tive and on cART. We used the standard TZM-bl (NIH 
AIDS Reagent Program) assay [29, 30] to determine 
neutralizing antibody titers when infecting with HIV-1 
tier 2 PRB926-04.A9.4237 (subtype B) [31], tier 1 HxB2.
DG (subtype B) [32], 93UG065 (subtype D)NIH ARP, and 
Q168ENVa2 (subtype A) [33] Env-pseudotyped viruses. 
A rapid analysis of the neutralizing antibodies pre- and 
4 weeks post-vaccination were carried out with 1:30 dilu-
tions of participants’ sera and luciferase reporter gene 
expression was determined with Britelite (Perkin Elmer) 
using a Victor V plate reader (Perkin Elmer). We found 
approximately 50% of subjects’ sera in SAV001 +  adju-
vant and SAV001 without adjuvant showed an elevated 
neutralizing antibody level against HIV-1 subtypes B, D, 
and A (Fig.  6a). Some subjects’ sera contain high levels 
of neutralizing activities. In order to determine the level 
of neutralizing antibodies in samples showing close to 
100% neutralization, dilutions of participants’ plasma 
(from 1/10 to 1/2430) were made and neutralization 
activity was measured through the reduction in lucif-
erase reporter gene expression in TZM-bl cells follow-
ing a 48-h incubation period with a single round of virus 
infection (Fig. 6b). As expected, the enrolled volunteers, 
Table 3 Adverse reactions caused by SAV001 vaccination
For each level of subject summarization, a subject was counted once if the patient reported 1 or more events. Adverse events were coded using MedDRA, Version 
15.1. Percentages were calculated using the number of patients in the Safety Set within each treatment as the denominator. Adverse event (AE), local reaction, clinical 
laboratory, vital signs, physical examinations, and plasma HIV-1 RNA levels were assessed from the administration of the study vaccine (Day 1) and continued until 
completion of the study visit at Day 365. An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the study 
vaccine, whether or not it was considered to be related to the vaccine. A serious AE (SAE) was defined as any untoward medical occurrence, if it resulted in death or 
was life threatening, required inpatient hospitalization or persistent or significant disability
AE adverse event
a Number of AEs = the total number of AEs at each level of summarization
b Subject was counted once according to the maximum intensity experienced if the patient reported 1 or more AEs
c Subject was counted once according to the most related if the patient reported 1 or more AEs. An AE (diarrhea) for Patient 3001018 in SAV001 group was originally 
considered to be possibly related to study drug. Follow-up communication, however, indicated that the event occurred when the patient took his antiretroviral 
medication on an empty stomach. Given the updated information, the investigator revised his assessment of the event to be unrelated to study drug. Because the 
follow-up communication occurred subsequent to the database being locked, the value in the database was not revised
Group 1 Group 2
SAV001 (n = 13) Placebo (n = 4) SAV001 + A (n = 12) Placebo + A (n = 4)
n (%) Number of AEsa n (%) Number of AEsa n (%) Number of AEsa n (%) Number of AEsa
Any AE 9 (69.2) 17 2 (50.0) 2 9 (75.0) 30 4 (100.0) 13
Any serious AE 0 0 0 0 0 0 0 0
AE by maximum intensityb
 Mild 6 (46.2) 12 2 (50.0) 2 6 (50.0) 23 3 (75.0) 12
 Moderate 2 (15.4) 4 0 0 3 (25.0) 7 1 (25.0) 1
 Severe 1 (7.7) 1 0 0 0 0 0 0
 Potentially life threatening 0 0 0 0 0 0 0 0
AE by relationshipc
 Not related 6 (46.2) 13 1 (25.0) 1 6 (50.0) 24 2 (50.0) 11
 Unlikely 2 (15.4) 3 1 (25.0) 1 2 (16.7) 5 1 (25.0) 1
 Possible 1 (7.7) 1 0 0 0 0 1 (25.0) 1
 Probable 0 0 0 0 0 0 0 0
 Definite 0 0 0 0 1 (8.3) 0 0 0
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even before vaccination with SAV001, showed high lev-
els of neutralizing antibody titres. Sixteen out of 27 com-
pletely tested subjects had neutralizing antibodies against 
the subtypes B, D, and A pseudotyped viruses at entry 
(Fig. 6). After a single-dose SAV001 vaccination, 5 out of 
10 study subjects in SAV001 + Adjuvant group showed 
elevated neutralizing antibody titres against HIV-1 B, D, 
and A subtypes (Fig.  6). Five out of 13 subjects’ plasma 
from the SAV001 without adjuvant showed elevated neu-
tralizing antibodies against subtype B, and 6 out of 13 
subjects showed elevated neutralizing antibodies against 
subtypes D and A. Similarly, Placebo +  adjuvant group 
and Placebo group also showed some neutralizing anti-
bodies at 4 weeks after vaccination. The level of elevated 
antibody titres were not related to the viral loads (only 
three subjects showed 20–50 copies of viral RNA/ml) nor 
the changing in CD4 cell counts (data not shown).
Discussion
This randomized, observer–blinded, placebo–controlled 
Phase I study was designed to assess safety and tolerabil-
ity as primary end-points, and humoral immunogenicity 
as a secondary end-point of a killed whole-HIV-1 vac-
cine, SAV001. To our knowledge, this is the first human 
P=0.032
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Fig. 4 Humoral immune responses of SAV001 vaccine. The humoral immune response was evaluated by assessment of antibody titres against p24, 
p17, gp120, and gp41 by ELISA. Microtiter plates were coated with specific HIV‑1 recombinant antigens (p24, p17, gp120, and gp41 derived from 
HIV‑1 IIIB (Immuno Diagnostics, USA) and serial dilutions of subject sera reacted against the specific antigens. The plates were read on the plate 
reader at 450 nm. Levels of antibodies in subjects from the entry and from week 4 to week 52 after vaccination were analyzed; p24 antibody (a), p17 
antibody (b), gp120 antibody (c), and gp41 antibody (d). Numbers in the x‑axis represent entry (E) and weeks after vaccination
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clinical trial with a killed whole-HIV-1 vaccine and the 
results of this study were highly encouraging. The single 
intramuscular administration of 100  µg of the SAV001 
with or without adjuvant was safe and well tolerated in 
the studied cohort, as there were no potentially life-
threatening AEs, SAEs, deaths, or AEs leading to study 
termination in any of the 33 enrolled subjects.
The greatest concern in the killed whole-virus vac-
cine strategy for HIV is whether the virus is completely 
inactivated. This concern for safety would impede any 
large scale production of the vaccine which is necessary 
to decrease the cost and the widespread use of HIV vac-
cine application, especially in developing countries. In 
the present study, we succeeded in generating a safe inac-
tivated vaccine suitable for mass manufacture. To fur-
ther ensure the safety of the vaccine, we deleted the nef 
gene for attenuation, and used both chemical (AT-2) and 
physical (γ-irradiation) inactivation to provide complete 
Fig. 5 SAV001 elicits antibodies that recognize HIV‑1 envelope glycoproteins at the surface of infected cells. CEM.NKr cells infected with full‑length 
NL4.3 GFP ADA Env (WT) (a, c, e and g) or deleted for nef and vpu (N‑U‑) (b, d, f and h) were stained at 48 h post‑infection with 1/1000 dilution of 
HIV + sera from Placebo‑ (a and b), Placebo + Adjuvant‑ (c and d), SAV001‑ (e and f) or SAV001 + Adjuvant‑ (g and h) vaccinees and then fluo‑
rescently labeled with an Alexa‑Fluor‑647 conjugated anti‑human IgG secondary Ab [27, 28, 36]. Shown is the mean fluorescent intensity (MFI) of 
staining by sera from study participants. Statistical significance was tested using a paired t test (*p < 0.05)
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Fig. 6 Neutralizing antibody response after vaccination. The analysis of the neutralizing antibodies before (green bar) and 4 weeks after (red bar) 
vaccination were carried out with 1:30 dilutions of sera and luciferase reporter gene expression was determined with Britelite (Perkin Elmer) using a 
Victor V plate reader (Perkin Elmer) (a). Neutralization activity of serial dilutions of high neutralizing antibodies of participants’ sera (red numbers on 
Fig. 5a) at both pre‑ and post‑vaccination, using PRB926‑04.A9.4237 (subtype B) and Q168ENVa2 (subtype A). Each data point represents the aver‑
age IC50 of a single serum sample tested with the either virus, and the data from pre‑ and post‑vaccination samples were paired for comparison (b). 
NA not available
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killing. The test for in vitro replication of SAV001 using 
the most sensitive methods showed that virus replication 
was absent even after 10 consecutive passages of human 
T lymphocytes after exposure (infection) to a large 
amount of the vaccine. Furthermore, following immu-
nization, highly sensitive, external-nested PCR amplifi-
cations using vaccine-specific primers on the viral RNA 
in plasma confirmed the lack of any vaccine strain virus 
genome. In contrast, the external-nested PCR amplifica-
tion by our generic HIV-1 primer sets was able to amplify 
HIV-1 RNA despite undetectable viral loads by the less 
sensitive Roche Amplicor assay (<50 copies/ml). Pyrose-
quencing of these PCR products before and after immu-
nization with SAV001 again confirmed the lack of HIV-1 
NL4-3 in over 70,000 HIV sequence reads and the pres-
ence of only patient-specific HIV-1 strains. These results 
provide very strong evidence that the technologies 
applied in this study completely inactivated the HIV-1 
and ensured the safety of the vaccine recipients.
Despite the complete inactivation of gmHIV-1NL4-3 
virus used in this present study, we only enrolled HIV-1 
positive asymptomatic volunteers based on discussions 
with the US FDA. Therefore, even though the study is 
designed for safety and tolerability evaluation, the nature 
of the study limited our ability to assess the immunology 
of vaccine formulations. Previous studies have shown 
that HIV-1 infection elicits antibody responses to pro-
teins encoded by HIV-1 gag, pol and env genes, and the 
antibody response to various proteins appears at differ-
ent stages of infections [37]. As expected, most of the 
subjects in our study had a high baseline antibody titer 
against viral structural proteins. However, with a single 
SAV001 intramuscular vaccination, the humoral immune 
response was significantly increased by boosting second-
ary anti-HIV antibody responses in vaccinated groups 
suggesting a strong immunogenicity of the SAV001 
vaccine.
A major goal of HIV-1 vaccine research is the design 
of immunogens capable of inducing protective levels 
of broadly neutralizing antibodies that bind to the viral 
envelope glycoprotein and neutralize the infectivity of 
HIV-1 [21]. Earlier reports described monoclonal anti-
bodies, including a pair of somatic variants that neutral-
ized over 90% of circulating HIV-1 isolates [38, 39]. The 
importance of the design of immunogens, especially the 
trimeric form of the envelope glycoproteins, capable of 
inducing broadly neutralizing antibodies is the major 
focus of the current HIV-1 vaccine research [40, 41]. 
Even though our killed whole-gmHIV-1NL4-3 virus was 
purified and completely inactivated through combined 
chemical and physical inactivation processes, its Env gly-
coproteins were not readily shed and were still functional 
(Fig. 1e–l). Our results suggest that SAV001 vaccine will 
mimic natural infection through its native viral structure, 
especially the native form of envelope glycoprotein which 
is crucial for eliciting broadly neutralizing antibodies. 
Indeed, when compared to placebo control, our data sup-
ported this hypothesis as SAV001 was able to stimulate 
anti-gp120 antibodies in plasma that could recognize 
trimeric Env glycoproteins at the surface of infected cell. 
Although most of subjects were infected with HIV-1 
subtype B in our trial (Table 1), sera from these subjects 
were able to neutralize not only subtype B but also sub-
types A and D which is consistent with the notion that 
HIV-1 superinfection is a limited event [42–45] particu-
larly those who have been infected with HIV-1 for more 
than several months. Thus, HIV-1 vaccine based on one 
subtype may be able to protect against infections of other 
subtypes. The immune response studies in HIV-negative 
subjects in our Phase II clinical trial may reveal this pos-
sibility. Furthermore, we tried to correlate the level of 
viral loads with the level of neutralizing antibodies in 
order to understand why many participants showed ele-
vated neutralizing antibody titres at 4  weeks after vac-
cination in all four groups. Only three subjects showed 
detectable levels of viral loads (20–50 copies/ml), with no 
correlations between the viral loads and the level of neu-
tralizing antibodies.
Conclusion
SAV001, the genetically modified and killed whole-HIV-1 
vaccine, is safe and well tolerated after a single intramus-
cular injection. The combination of chemical and physi-
cal inactivation procedures is adequate to completely 
kill the genetically modified HIV-1 NL4-3 virus while 
retaining the function and immunogenicity of viral pro-
teins. Vaccination with SAV001 could enhance humoral 
immune responses including broadly neutralizing anti-
body production in HIV-1 negative individuals. There-
fore, SAV001 represents a promising starting point for 
development of a safe and effective HIV-1 vaccine using 
the killed whole virus approach.
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